Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant

Non-antibody scaffold proteins are used for a range of applications, especially the assessment of protein–protein interactions within human cells. The search for a versatile, robust and biologically neutral scaffold previously led us to design STM (stefin A triple mutant), a scaffold derived from the intracellular protease inhibitor stefin A. Here, we describe five new STM-based scaffold proteins that contain modifications designed to further improve the versatility of our scaffold. In a step-by-step approach, we introduced restriction sites in the STM open reading frame that generated new peptide insertion sites in loop 1, loop 2 and the N-terminus of the scaffold protein. A second restriction site in ‘loop 2’ allows substitution of the native loop 2 sequence with alternative oligopeptides. None of the amino acid changes interfered significantly with the folding of the STM variants as assessed by circular dichroism spectroscopy. Of the five scaffold variants tested, one (stefin A quadruple mutant, SQM) was chosen as a versatile, stable scaffold. The insertion of epitope tags at varying positions showed that inserts into loop 1, attempted here for the first time, were generally well tolerated. However, N-terminal insertions of epitope tags in SQM had a detrimental effect on protein expression.

[1]  M. K. Shaw,et al.  Synthesis of Macromolecules by Escherichia coli near the Minimal Temperature for Growth , 1967, Journal of bacteriology.

[2]  G. Caponigro,et al.  Green fluorescent protein as a scaffold for intracellular presentation of peptides. , 1998, Nucleic acids research.

[3]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[4]  Andreas Plückthun,et al.  Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.

[5]  A. Barrett,et al.  Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. , 1986, The Journal of biological chemistry.

[6]  D. Craik,et al.  Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design. , 2006, The Biochemical journal.

[7]  Steven Johnson,et al.  Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays , 2008, Journal of biology.

[8]  大房 健 基礎講座 電気泳動(Electrophoresis) , 2005 .

[9]  I. Björk,et al.  The role of the second binding loop of the cysteine protease inhibitor, cystatin A (stefin A), in stabilizing complexes with target proteases is exerted predominantly by Leu73. , 2002, European journal of biochemistry.

[10]  L. Wilkinson Immunity , 1891, The Lancet.

[11]  Jan Tkac,et al.  Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold. , 2007, Analytical chemistry.

[12]  R. Ladner,et al.  Constrained peptides as binding entities. , 1995, Trends in biotechnology.

[13]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[14]  R. Jerala,et al.  Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions. , 1999, Journal of molecular biology.

[15]  T. Prasthofer,et al.  Characterization by spectroscopic, kinetic and equilibrium methods of the interaction between recombinant human cystatin A (stefin A) and cysteine proteinases. , 1995, The Biochemical journal.

[16]  S. Laurenson,et al.  Design and validation of a neutral protein scaffold for the presentation of peptide aptamers. , 2005, Journal of molecular biology.

[17]  P. van Endert,et al.  Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. , 2002, Molecular immunology.

[18]  W. Bode,et al.  The 2.0 A X‐ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. , 1988, The EMBO journal.

[19]  R. Huber,et al.  The refined 2.4 A X‐ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. , 1990, The EMBO journal.

[20]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[21]  J. Mccoy,et al.  A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the E. coli Cytoplasm , 1993, Bio/Technology.

[22]  A. Plückthun,et al.  Designed to be stable: Crystal structure of a consensus ankyrin repeat protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Kees Jalink,et al.  Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. , 2003, Immunity.

[24]  A. Koide,et al.  The fibronectin type III domain as a scaffold for novel binding proteins. , 1998, Journal of molecular biology.

[25]  Jason J. Davis,et al.  Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms. , 2009, Analytical chemistry.

[26]  M. Kainosho,et al.  Solution structure of a human cystatin A variant, cystatin A2-98 M65L, by NMR spectroscopy. A possible role of the interactions between the N- and C-termini to maintain the inhibitory active form of cystatin A. , 1995, Biochemistry.

[27]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[28]  V. Turk,et al.  Protein inhibitors of cysteine proteinases. III. Amino-acid sequence of cystatin from chicken egg white. , 1983, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[29]  Arne Skerra,et al.  Anticalins as an alternative to antibody technology , 2005, Expert opinion on biological therapy.

[30]  I. Björk,et al.  The contribution of N-terminal region residues of cystatin A (stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B, and cathepsin L. , 1999, Biochemistry.

[31]  Steven Johnson,et al.  Surface-immobilized peptide aptamers as probe molecules for protein detection. , 2008, Analytical chemistry.

[32]  M. Uhlén,et al.  A combinatorial library of an α-helical bacterial receptor domain , 1995 .

[33]  H. Kolmar Alternative binding proteins: Biological activity and therapeutic potential of cystine‐knot miniproteins , 2008, The FEBS journal.

[34]  C. Fisher,et al.  Modification of a PCR-based site-directed mutagenesis method. , 1997, BioTechniques.

[35]  J. Waltho,et al.  Comparison of backbone dynamics of monomeric and domain‐swapped stefin A , 2004, Proteins.

[36]  J. Waltho,et al.  The role of Gly-4 of human cystatin A (stefin A) in the binding of target proteinases. Characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L. , 1998, Biochemistry.

[37]  V. Turk,et al.  Major differences in stability and dimerization properties of two chimeric mutants of human stefins , 2001, Proteins.

[38]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[39]  V. Turk,et al.  Human cystatin, a new protein inhibitor of cysteine proteinases. , 1984, Biochemical and biophysical research communications.

[40]  B. Lenarčič,et al.  Folding studies of the cysteine proteinase inhibitor--human stefin A. , 1991, Biochimica et biophysica acta.

[41]  J. Waltho,et al.  The three-dimensional solution structure of human stefin A. , 1995, Journal of molecular biology.

[42]  P. Colas The eleven-year switch of peptide aptamers , 2008, Journal of biology.

[43]  A. Skerra Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.

[44]  T. Mulhern,et al.  Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold. , 2006, Protein engineering, design & selection : PEDS.

[45]  R. Brent,et al.  An artificial cell-cycle inhibitor isolated from a combinatorial library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Wenmiao Shu,et al.  Highly specific label-free protein detection from lysed cells using internally referenced microcantilever sensors. , 2008, Biosensors & bioelectronics.

[47]  Torsten Schwede,et al.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..

[48]  김삼묘,et al.  “Bioinformatics” 특집을 내면서 , 2000 .

[49]  J. Waltho,et al.  Structural characterisation of human stefin A in solution and implications for binding to cysteine proteinases. , 1994, European journal of biochemistry.

[50]  C Marque,et al.  Human abdominal EHG processing for uterine contraction monitoring. , 1989, Biotechnology.

[51]  A. Barrett,et al.  Cystatin-like cysteine proteinase inhibitors from human liver. , 1984, The Biochemical journal.

[52]  N. Bryan,et al.  Cardioprotective effects of thioredoxin in myocardial ischemia and the reperfusion role of S-nitrosation , 2004 .

[53]  Roger Brent,et al.  Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.

[54]  F. Hoppe-Seyler,et al.  Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding , 2002, Cellular and Molecular Life Sciences CMLS.

[55]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[56]  유영제,et al.  Biotechnology에서 배우는 교훈 , 2006 .

[57]  D. Turk,et al.  Crystal structure of Stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo- and exopeptidases. , 2003, Journal of molecular biology.

[58]  Debjani Paul,et al.  Label-free detection of protein interactions with peptide aptamers by open circuit potential measurement , 2008 .

[59]  H. Kolmar,et al.  Alternative binding proteins get mature: Rivalling antibodies , 2008, The FEBS journal.

[60]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[61]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[62]  P. Ferrigno,et al.  A peptide aptamer to antagonize BCL-6 function , 2006, Oncogene.

[63]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[64]  Eric Beitz,et al.  TeXshade: shading and labeling of multiple sequence alignments using LaTeX2e , 2000, Bioinform..

[65]  Andreas Plückthun,et al.  Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. , 2008, Journal of molecular biology.